Gene transfer of noncleavable cell surface mutants of human CD154 induces the immune response and diminishes systemic inflammatory reactions

Journal of Immunotherapy

Volumn 30, Issue 7, 2007, Pages 694-704

  Masuta, Yukari ^a   Kato, Kazunori ^a   Tomihara, Kei ^a   Nakamura, Kiminori ^a   Sasaki, Katsunori ^a   Takahashi, Satoshi ^b   Hamada, Hirofumi ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

CD154 mutant; Gene therapy; Immune response; Systemic inflammatory response

Indexed keywords

ADENOVIRUS VECTOR; CD40 LIGAND; MUTANT PROTEIN; PROTEIN CD154 M3; PROTEIN CD154 M4; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LEUKEMIA; CELL DIVISION; CELL INFILTRATION; CELL INTERACTION; CELL SURFACE; CELL TRANSPLANTATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE TRANSFER; GENETIC TRANSFECTION; GLOMERULONEPHRITIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; LIVER; LIVER CELL; MONONUCLEAR CELL; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; TUMOR CELL; WILD TYPE;

ANIMALS; CD40 LIGAND; GENE THERAPY; HUMANS; INFLAMMATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, NUDE; MUTANT PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; TRANSFECTION;

EID: 34748913584     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31811a5c51     Document Type: Article

References (55)

1. Hollenbaugh D, Grosmaire LS, Kullas CD, et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J. 1992;11:4313-4321.
2. Banchereau J, Bazan F, Blanchrad D, et al. The CD40 antigen and its ligand. Annu Rev Immunol. 1994;12:881-922.
3. Grewal IS, Flavell RA. The CD40 ligand. At the center of the immune universe? Immunol Res. 1997;16:59-70.
4. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591-594.
5. Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther. 2003;10:1-13.
6. Luft T, Luetjens P, Hubertus H, et al. IFN-γ enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. Int Immunol. 2001;14:367-380.
7. Bleharski JR, Niazi KR, Sieling PA, et al. Signaling lymphocytic activation molecule is expressed on CD40 ligand-activated dendritic cells and directly augments production of inflammatory cytokines. J Immunol. 2001;167:3174-3181.
8. Xu Y, Song G. The role of CD40-CD154 interaction in cell immunoregulation. J Biomed Sci. 2004;11:426-438.
9. Kato K, Cantwell MJ, Sharma S, et al. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest. 1998;101:1133-1141.
10. Takahashi S, Rousseau RF, Yotnda P, et al. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum Gene Ther. 2001;12:659-670.
11. Takahashi S, Yotnda P, Rousseau RF, et al. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patient with non-Hodgkin's lymphoma. Cancer Gene Ther. 2001;8:378-387.
12. Dotti G, Savoldo B, Takahashi S, et al. Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells: a model for immunotherapy. Exp Hematol. 2001;29:952-961.
13. Biagi E, Yvon E, Dotti G, et al. Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells. Hum Gene Ther. 2003;14:545-559.
14. Li L, Biagi E, Allen C, et al. Rapid and efficient nonviral gene delivery of CD40L to primary chronic lymphocytic leukemia cells. Cancer Gene Ther. 2006;13:215-224.
15. Wierda WG, Cantwell MJ, Woods SJ, et al. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000;96:2917-2924.
16. Messmer D, Kipps TJ. CD154 gene therapy for human B-cell malignancies. Ann NY Acad Sci. 2005;1062:51-60.
17. Biagi E, Rousseau RF, Yvon E, et al. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2005;11:6916-6923.
18. Rousseau RF, Biagi E, Dutour A, et al. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood. 2006;107:1332-1341.
19. Pietravalle F, Lecoanet-Henchoz S, Aubry JP, et al. Cleavage of membrane-bound CD40 ligand is not required for inducing B cell proliferation and differentiation. Eur J Immunol. 1996;26:725-728.
20. Pietravalle F, Lecoanet-Henchoz S, Blasey H, et al. Human native soluble CD40L is a biologically active trimer, processed inside microsomes. J Biol Chem. 1996;271:5965-5967.
21. Wykes M, Poudrier J, Lindstedt R, et al. Regulation of cytoplasmic, surface and soluble forms of CD40 ligand in mouse B cells. Eur J Immunol. 1998;28:548-559.
22. Kato K, Santana-Sahagun E, Rassenti LZ, et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest. 1999;104:947-955.
23. Tamura N, Kobayashi S, Kato K, et al. Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. J Rheumatol. 2001;28:2583-2590.
24. Danese S, Katz JA, Saibeni S, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut. 2003;52:1435-1441.
25. Andre P, Nannizzi-Alaimo L, Prasad SK, et al. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation. 2002;106:869-896.
26. Lee SP, Ataga KI, Orringer EP, et al. Biologically active CD40 ligand is elevated in sickle cell Anemia. Potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol. 2006;26:1626-1631.
27. Srinivasa Prasad KS, Andre P, He M, et al. Soluble CD40 ligand induces b3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci USA. 2003;100:12367-12371.
28. Pear WS, Nolan GP, Scott ML, et al. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA. 1993;90:8392-8396.
29. Wakimoto H, Yoshida Y, Aoyagi M, et al. Efficient retrovirus-mediated cytokine-gene transduction of primary-cultured human glioma cells for tumor vaccination therapy. Jpn J Cancer Res. 1997;88:296-305.
30. Shinoura N, Yoshida Y, Satada A, et al. Apoptosis by retrovirus-and adenovirus-mediated gene transfer of Fas ligand to glioma cells: implications for gene therapy. Hum Gene Ther. 1993;9:1983-1993.
31. Yoshida Y, Hamad H. Adenovirus-mediated inducible gene expression through tetracycline-controllable transactivator with nuclear localization signal. Biochem Biophys Res Commun. 1997;230:426-430.
32. Dehari H, Ito Y, Nakamura T, et al. Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer. Cancer Gene Ther. 2003;10:75-85.
33. Tanaka T, Huang J, Hirai S, et al. Carcinoembryonic antigen-targeted selective gene transfer for gastric cancer through FZ33 fiber-modified adenovirus vectors. Clin Cancer Res. 2006;12:3803-3813.
34. Kanegae Y, Lee G, Sato Y, et al. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucleic Acid Res. 1995;23:3816-3821.
35. Nyberg-Hoffman C, Shabram P, Li W, et al. Sensitivity and reproducibility in adenoviral infectious titer determination. Nat Med. 1997;3:808-811.
36. Zhang WW, Koch PE, Roth JA. Detection of contamination in a recombinant adenoviral preparation by PCR. Biotechniques. 1995;18:444-447.
37. Armitage RJ. Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol. 1994;6:407-413.
38. Galli G, Nuti S, Tavarini S, et al. CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J Exp Med. 2003;197:1051-1057.
39. Caux C, Massacrier C, Vanbervliet B, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med. 1994;180:1263-1272.
40. Durie FH, Foy TM, Masters SR, et al. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today. 1994;15:406-411.
41. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med. 1993;177:925-935.
42. Stripecke R, Levine AM, Pullarkat V, et al. Immunotherapy with acute leukemia cells modified into antigen-presenting cells: ex vivo culture and gene transfer methods. Leukemia. 2002;16:1974-1983.
43. Yellin MJ, D'Agati V, Parkinson G, et al. Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum. 1997;40:124-134.
44. Stout RD, Suttles J. The many roles of CD40 in cell-mediated inflammatory responses. Immunol Today. 1996;17:487-492.
45. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 1998;16:111-135.
46. Perez C, Albert I, DeFay K, et al. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell. 1990;63:251-258.
47. Pascal S, Nils H, Jean-Luc B, et al. Conversion of membrane-bound Fas (CD95) ligand to its soluble forms is associated with downregulation of its proapoptotic activity and loss toxicity. J Exp Med. 1998;187:1205-1213.
48. Graf D, Muller S, Korthauer U, et al. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol. 1995;25:1749-1754.
49. Mazzei GJ, Edgerton MD, Losberger C, et al. Recombinant soluble trimeric CD40 ligand is biologically active. J Biol Chem. 1995;270:7025-7028.
50. Wendtner CM, Kofler DM, Theiss HD, et al. Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. Blood. 2002;100:1655-1661.
51. Tomihara K, Kato K, Masuta Y, et al. Gene transfer of the CD40-ligand to human dendritic cells induces NK-mediated anti-tumor effects against human carcinoma cells. Int J Cancer. 2007;120:1491-1498.
52. Chu P, Deforce D, Pedersen IM, et al. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99:3854-3859.
53. Dicker F, Kater AP, Fukuda T, et al. Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. Blood. 2005;105:3193-3198.
54. Yellin MJ, Brett J, Baum D, et al. Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals. J Exp Med. 1995;182:1857-1864.
55. Schmitz V, Dombrowski F, Prieto J, et al. Induction of murine liver damage by overexpression of CD40 ligand provides an experimental model to study fulminant hepatic failure. Hepatology. 2006;44:430-439.